Eight patients with severe hidradenitis were treated for 1 year with adalimumab in a standard regimen and were subsequently followed for 1 year. All patients improved within 4-6 weeks and laboratory parameters of C-reactive protein (CRP) and leukocyte count reduced significantly during treatment. The mean CRP value reduced from 42.5 to 12.8 mg/l at 6 weeks and to 5.2 at 6 months. The gene discussed is CRP; the disease is hidradenitis.